New Drug Offers Extended Life for Advanced Pancreatic Cancer Patients
An innovative pill, daraxonrasib, has been shown to extend the lives of people with advanced pancreatic cancer, increasing survival times significantly over traditional chemotherapy, according to a recent study. The drug blocks a protein mutation responsible for cancer growth, introducing a promising new treatment option.
- Country:
- United States
An experimental medication, daraxonrasib, has demonstrated a remarkable ability to prolong the lives of individuals with advanced pancreatic cancer, potentially paving the way for improved treatment options. Researchers announced that this novel drug nearly doubles survival time compared to traditional chemotherapy treatments.
Daraxonrasib targets a specific protein mutation that promotes tumor growth, a challenge that has perplexed oncologists for decades. In a study involving 500 patients, those given the drug lived a median of 13.2 months, outperforming chemotherapy patients who lived 6.7 months. The results were presented at a leading oncology conference in Chicago.
Despite some side effects like severe rashes and mouth sores, the drug offers a significant quality of life improvement by reducing pain. Patients were able to remain on treatment longer than with chemotherapy, suggesting the survival advantage may increase over time, according to researchers.
The drug was developed by Revolution Medicines, which funded the study, and the U.S. FDA is fast-tracking its review. Oncology specialists are hopeful about daraxonrasib's potential as a new standard care for metastatic pancreatic cancer.
(With inputs from agencies.)
ALSO READ
Maharashtra FDA's Crackdown Leads to 33 Arrests and 27 Closures
Maharashtra FDA Confiscates Patanjali and Other Medicines for Misleading Claims
Maharashtra FDA Cracks Down on Misleading Medicinal Ads, Seizes Drugs
Maharashtra FDA Cracks Down on Food Adulteration: Dozens Detained
FDA Cracks Down on Illegal Food Items, Arrests Six in Thane
Google News